DRR168581
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.350
- CHOLESTEROL_HOMEOSTASIS+0.320
- HYPOXIA+0.290
- MTORC1_SIGNALING+0.290
- PANCREAS_BETA_CELLS+0.290
- PEROXISOME+0.290
- PROTEIN_SECRETION+0.280
- GLYCOLYSIS+0.240
- MYC_TARGETS_V1+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- WNT_BETA_CATENIN_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.360
- INTERFERON_GAMMA_RESPONSE-0.340
- HEDGEHOG_SIGNALING-0.200
- UV_RESPONSE_DN-0.190
- ANGIOGENESIS-0.170
- ALLOGRAFT_REJECTION-0.160
- IL2_STAT5_SIGNALING-0.140
- OXIDATIVE_PHOSPHORYLATION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1XJ-01A-11R-A14M-07 | — | C | 0.734 |
| 2 | SRR25617840 | — | B | 0.710 |
| 3 | MNG1229 | — | — | 0.692 |
| 4 | TCGA-18-3411-01A-01R-0980-07 | — | cohortSQ2 | 0.692 |
| 5 | 56218_S133 | — | cohortSQ1 | 0.681 |
| 6 | DRR168513 | — | — | 0.679 |
| 7 | TCGA-BT-A3PH-01A-11R-A220-07 | — | — | 0.678 |
| 8 | DRR168587 | — | — | 0.677 |
| 9 | R397 | — | — | 0.674 |
| 10 | SRR13311180 | — | — | 0.673 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |